ClinicalTrials.gg
Enrolling by invitationNCT06462989HEART-AIUpdated Oct 13, 2026

Harnessing ECG Artificial Intelligence for Rapid Treatment and Accurate Interpretation

An interventional study of ECHONEXT in Structural Heart Abnormality and Structural Heart Disease, sponsored by Montreal Heart Institute. Enrolling by invitation at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Montreal Heart Institute · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 13, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5,700
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

HEART-AI is a pragmatic randomized trial currently active at Montreal Heart Institute, with planned multicenter expansion testing whether an artificial intelligence (AI) score from a routine 12-lead electrocardiogram (ECG) helps clinicians identify structural heart disease sooner. Structural heart disease includes reduced heart pumping function, valve disease, pulmonary hypertension, thickened heart muscle and fluid around the heart. The study plans to enroll 5,700 adults seen in outpatient clinics or ambulatory emergency departments who have no known structural heart disease.

Patients are assigned equally to standard care with or without the EchoNext AI risk score and echocardiography recommendation. For high-risk patients, EchoNext recommends a transthoracic echocardiogram (TTE, an ultrasound of the heart) within 2 to 4 weeks, no later than 30 days. Low-risk patients receive routine care, with TTE when clinically indicated. Clinicians retain responsibility for all care decisions. The score is calculated in both groups but shown only in the AI group.

The main outcome is the proportion of patients with structural heart disease documented on a clinical TTE within 30 days of their first study ECG. Other outcomes include diagnoses within 12 months, time to TTE and diagnosis, imaging use, management changes and model performance.

Read the detailed description

Design and population HEART-AI is a pragmatic, parallel-group trial currently active at one site, Montreal Heart Institute, with planned multicenter expansion with patient-level 1:1 randomization through DeepECG.ai at review of the first eligible clinically indicated ECG. Randomization is stratified by center, biological sex (administrative sex as proxy), and setting (outpatient versus ambulatory emergency department), using permuted blocks of varying size. Allocation remains fixed for subsequent ECGs; only the first ECG is analyzed. The planned expansion includes Montreal Heart Institute (MHI), McGill University Health Centre, University of Ottawa Heart Institute, Jewish General Hospital, University Health Network, Marienkrankenhaus Hamburg, Sorel and Joliette. Each new site activates only after ethics approval and an executed data-processing agreement. Study completion is anticipated in 2027. MHI completed setup in 2025 and continues randomizing. The target is 5,700 patients.

Intervention and workflow Providers confirm eligibility before randomization and record their TTE ordering intent and intended priority before any AI result is displayed. The intervention arm receives standard care plus the EchoNext SHD risk score and TTE recommendation: high risk, TTE within 2 to 4 weeks (≤30 days); low risk, routine care and TTE only if clinically indicated. The control arm receives standard ECG interpretation and clinical judgment without displayed AI scores or recommendations. Scores are computed in both arms. Providers manage both arms and retain full clinical autonomy. The post-ECG form records TTE referral, intended priority (≤30 or >30 days), and AI use in the intervention arm. Model weights remain frozen throughout the trial.

SHD definition and outcome ascertainment SHD is any of: LVEF ≤45% measured by Simpson biplane; moderate or greater RV systolic dysfunction (TAPSE ≤17 mm, fractional area change ≤35%, or moderate-or-worse impairment on visual assessment); systolic pulmonary artery pressure ≥45 mm Hg; moderate or greater mitral, tricuspid, pulmonic or aortic regurgitation or aortic stenosis; septal or posterior LV wall thickness ≥1.3 cm; or moderate or large pericardial effusion. Two trained abstractors blinded to arm assess clinical TTE reports. Disagreements are adjudicated by a study cardiologist not involved in the patient's care.

The primary numerator is any qualifying clinical TTE documenting SHD within 30 days of the index ECG; the denominator is all randomized patients. The earliest SHD-positive clinical TTE is used. Patients without an accessible qualifying result at 30 days, including deaths, have no documented 30-day SHD diagnosis. Each SHD component is reported separately by arm. Primary analysis follows intention-to-treat and uses GEE logistic regression adjusted for center, sex and setting, clustered on provider. Secondary time-to-TTE and time-to-SHD analyses censor at 12 months and treat death as a competing event. Clinical and process outcomes are also reported by biological sex.

Monitoring A blinded interim at approximately 2,850 patients re-estimates the pooled 30-day SHD rate. There is no early stopping for efficacy or futility. No DSMB is constituted. An independent safety officer with no role in trial conduct or platform development reviews safety every 6 months, focusing on low-risk under-diagnosis and TTEs performed beyond the intended priority window. Seriant conducts independent analyses.

Outcome amendment rationale, October 4, 2026 The primary outcome is revised from time to SHD diagnosis to the proportion of randomized patients with clinical TTE-documented SHD within 30 days, aligning the registry with the revised multicenter grant's primary objective and sample-size calculation. This measures whether AI-guided prioritization closes the gap in timely SHD detection. Time to SHD diagnosis is retained as a secondary outcome with follow-up through 12 months.

This outcome amendment precedes any unblinded comparison of randomized study arms. There is no verification TTE substudy.

02

Conditions studied

  • Structural Heart Abnormality
  • Structural Heart Disease

Keywords

  • artificial intelligence
  • transthoracic echocardiogram
  • magnetic resonance imaging
03

In context

Lead sponsor

Montreal Heart Institute is the lead sponsor of 101 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Providers:

- Licensed healthcare professionals (physicians, nurse practitioners, physician assistants, and residents) who interpret ECGs in ambulatory cardiology clinics or emergency departments and have authority to order TTEs.

Patients:

  • Adults aged 18 years or older presenting to outpatient cardiology clinics or ambulatory emergency departments with unknown structural heart disease (SHD) status.
  • Either new patients with no prior cardiac diagnosis and no prior TTE on record, or surveillance patients whose most recent TTE was normal (no SHD) and performed at least 24 months ago.

ECGs:

- Standard 12-lead ECGs in XML format recorded after study initiation and successfully transmitted to DeepECG.ai.

Exclusion criteria

Exclusion Criteria:

Providers:

- None.

Patients:

- Inpatient or hospitalized patients at the time of . Patients randomized in the ambulatory emergency department who are subsequently hospitalized remain eligible.

ECGs:

- Failed automated quality checks, including poor technical quality or indiscernible QRS waveforms.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
5,700 participants (estimated)

Study arms

  • Experimental
    EchoNext AI-ECG risk score plus standard care

    Standard care plus the EchoNext structural heart disease risk score and TTE priority recommendation displayed through DeepECG.ai at review of the index 12-lead ECG. High risk: recommend TTE within 2 to 4 weeks (≤30 days). Low risk: routine care, TTE only if clinically indicated, and symptom monitoring. Scores are computed in both arms but displayed only in this arm. Model weights remain frozen for the trial. Before display, providers record TTE ordering intent and intended priority; after ECG review they record final referral and intended priority (≤30 or \>30 days). Providers retain full clinical autonomy.

    Other: ECHONEXT

  • No intervention
    Standard care without displayed EchoNext guidance

    Standard ECG interpretation with clinician judgment and physical examination for TTE referral. EchoNext SHD risk scores are computed but neither the score nor the TTE recommendation is displayed to providers. Before ECG interpretation, providers record TTE ordering intent and intended priority; final referral and intended priority (≤30 or \>30 days) are recorded afterward. Providers retain full access to medical records and full clinical autonomy.

Interventions

  • OtherECHONEXT

    EchoNext is an ECG-based artificial intelligence algorithm that predicts structural heart disease from a clinically indicated 12-lead ECG. Through DeepECG.ai, intervention-arm providers receive the SHD risk score and a TTE priority recommendation: high risk, TTE within 2 to 4 weeks (≤30 days); low risk, routine care and TTE only if clinically indicated. Scores are computed in both randomized arms but are displayed only in the intervention arm. Model weights remain frozen throughout the trial. This is single-encounter clinical decision support; providers retain full autonomy over referral and management.

06

What researchers measure

Primary outcomes

  1. Proportion of randomized patients with TTE-documented structural heart disease within 30 days

    Proportion of all randomized patients with at least one clinical TTE demonstrating prespecified structural heart disease (SHD) within 30 days of the index ECG, analyzed by intention-to-treat. SHD is any of: LVEF ≤45% by Simpson biplane; moderate or greater RV dysfunction (TAPSE ≤17 mm, fractional area change ≤35%, or moderate-or-worse visual impairment); systolic pulmonary artery pressure ≥45 mm Hg; moderate or greater mitral, tricuspid, pulmonic or aortic regurgitation or aortic stenosis; septal or posterior LV wall thickness ≥1.3 cm; or moderate or large pericardial effusion. Clinical TTE reports are abstracted by two assessors blinded to arm, with disagreements adjudicated. The earliest SHD-positive clinical TTE is used. Patients without an accessible qualifying clinical TTE result by day 30, including deaths, have no documented 30-day SHD diagnosis.

    Time frame: 30 days from the index ECG

Secondary outcomes

  1. Proportion of randomized patients with TTE-documented structural heart disease within 12 months

    Proportion of all randomized patients with echocardiographically-confirmed SHD on clinical TTE within 12 months of the index ECG, compared between arms using the prespecified SHD composite defined in the primary outcome. Outcome assessment is blinded to randomized arm. Analyses are reported overall and by biological sex.

    Time frame: 12 months from the index ECG

  2. Time from index ECG to clinical TTE

    Time from the index ECG to the first completed clinical TTE, compared between randomized arms overall and by EchoNext risk class. Time-to-event analyses include all randomized patients, censor at 12 months, and treat death as a competing event. Analyses are also reported by biological sex.

    Time frame: 12 months from the index ECG

  3. Intended TTE priority at the index ECG

    Proportion of patients assigned intended TTE priority ≤30 days versus \>30 days on the post-ECG questionnaire, compared between randomized arms overall and by EchoNext risk class and biological sex.

    Time frame: At baseline

  4. Provider concordance with EchoNext TTE recommendations

    Proportion of intervention-arm patients for whom a TTE is ordered within the EchoNext recommended window, overall and stratified by EchoNext risk class. High-risk patients are recommended TTE within 2 to 4 weeks (≤30 days); low-risk patients receive routine care with TTE when clinically indicated.

    Time frame: At baseline

  5. Time from index ECG to SHD diagnosis

    Time from the index ECG to the first clinical TTE documenting the prespecified SHD composite defined in the primary outcome. Analyze all randomized patients, censor at 12 months, and treat death as a competing event. Compare arms overall and by EchoNext risk class and biological sex. This outcome was retained as secondary when the primary outcome was changed to documented SHD within 30 days.

    Time frame: 12 months from the index ECG

  6. Diagnostic yield of clinical TTE

    Number of patients with SHD diagnosed on completed clinical TTE divided by the number of completed clinical TTEs, compared between arms overall and by EchoNext risk class. In high-risk patients, also report incremental yield as the arm difference in 30-day SHD diagnoses divided by the arm difference in completed 30-day clinical TTEs.

    Time frame: 30 days from the index ECG

  7. Net clinical TTE volume per 100 randomized patients

    Number of completed clinical TTEs per 100 randomized patients and the between-arm difference, overall and by EchoNext risk class. Also report clinical TTEs per SHD diagnosis to distinguish added imaging from improved targeting.

    Time frame: 30 days from the index ECG

  8. Documented management change after SHD diagnosis

    Proportion of patients diagnosed with SHD who have a documented specialty referral, initiation or uptitration of guideline-directed therapy, structural intervention, or right heart catheterization within 12 months. Compare randomized arms overall and by biological sex.

    Time frame: 12 months from the index ECG

  9. SHD diagnosis in low-risk patients by randomized arm

    Proportion of low-risk randomized patients with clinical TTE-documented SHD within 30 days, compared between arms as a safety and falsification outcome. A low-risk deficit may indicate under-diagnosis from deprioritization; an excess is interpreted as contamination or chance.

    Time frame: 30 days from the index ECG

  10. EchoNext diagnostic performance and algorithmic fairness

    Sensitivity, specificity, positive and negative predictive values of EchoNext against clinical TTE-confirmed SHD within 30 days in the control arm; intervention-arm estimates are reported separately. Assess equalized odds, calibration slope and predictive parity across age (\<65, 65-84, ≥85 years) and biological sex subgroups. Trial model weights remain frozen; subgroup recalibration is reported as a secondary analysis without changing the deployed model.

    Time frame: 30 days from the index ECG

  11. Pre-display TTE intent versus final referral decision

    Compare the clinician's TTE-ordering intent and intended priority recorded before any AI result is displayed with the final post-ECG referral decision and intended priority (≤30 versus \>30 days), by randomized arm and EchoNext risk class.

    Time frame: At baseline

  12. Reduced left ventricular ejection fraction diagnosed on clinical TTE

    Proportion of randomized patients with LVEF ≤45% measured by Simpson biplane on clinical TTE, reported separately by arm and biological sex as a component of the prespecified SHD composite.

    Time frame: 30 days from the index ECG

  13. Reduced right ventricular systolic function diagnosed on clinical TTE

    Proportion of randomized patients with moderate or greater RV dysfunction: TAPSE ≤17 mm, fractional area change ≤35%, or moderate-or-worse visual impairment. Report separately by arm and biological sex.

    Time frame: 30 days from the index ECG

  14. Pulmonary hypertension diagnosed on clinical TTE

    Proportion of randomized patients with systolic pulmonary artery pressure ≥45 mm Hg on clinical TTE, reported separately by arm and biological sex as a component of the SHD composite.

    Time frame: 30 days from the index ECG

  15. Valvular heart disease diagnosed on clinical TTE

    Proportion of randomized patients with moderate or greater mitral, tricuspid, pulmonic or aortic regurgitation, or aortic stenosis, on clinical TTE. Each valve lesion is reported separately by arm and biological sex as a component of the prespecified SHD composite.

    Time frame: 30 days from the index ECG

  16. Left ventricular hypertrophy diagnosed on clinical TTE

    Proportion of randomized patients with septal or posterior LV wall thickness ≥1.3 cm on clinical TTE, reported separately by arm and biological sex as a component of the SHD composite.

    Time frame: 30 days from the index ECG

  17. Pericardial effusion diagnosed on clinical TTE

    Proportion of randomized patients with moderate or large pericardial effusion on clinical TTE, reported separately by arm and biological sex as a component of the SHD composite.

    Time frame: 30 days from the index ECG

Other outcomes

  1. Describe the engagement of users and the overall utilization of the DeepECG platform algorithm in the clinical setting

    Number of ECGs accessed per user Number of days per user with at least 1 ECG accessed using the platform over total number of days the user is in the study (i.e. has access to the platform).

    Time frame: 18 months

  2. Intended TTE priority by ambulatory care setting

    Post-ECG intended TTE priority (≤30 days versus \>30 days), compared by randomized arm within outpatient and ambulatory emergency department settings.

    Time frame: At baseline

  3. Review additional qualitative feedback and insights captured after reading an ECG

    Narrative description put in the "other" field of the post-ECG questionnaire

    Time frame: 18 months

  4. Provider experience with EchoNext and DeepECG

    End-of-study provider survey assessing usability with the System Usability Scale, trust in automation and workflow impact. Analyses are stratified by technological literacy and provider gender, with optional GENESIS-PRAXY characterization.

    Time frame: At the end of the 27-month randomized main trial phase

  5. Assess the agreement of the user with the ECG-AI algorithm's interpretations according to practice type, number of years in practice, age of user and familiarity with AI tools (based on end of study questionnaire)

    Agreement (Yes/No) of the user with the ECG-AI algorithm's interpretation. Agreement is defined as the user clicking on "thumbs up" on the platform.

    Time frame: 18 months

  6. 30-day SHD diagnosis by prior TTE status and biological sex

    Prespecified subgroup analyses of the primary endpoint by new patient status (no prior TTE) versus surveillance patient status (most recent normal TTE at least 24 months previously), and separately by patient biological sex. Report arm-specific proportions, adjusted odds ratios and arm-by-subgroup interactions. These comparisons are hypothesis-generating.

    Time frame: 30 days from the index ECG

  7. Describe the agreement of the user with the ECG-AI algorithm's interpretation according to the diagnosis category of the ECG-AI (ischemic, arrythmia, chamber enlargement, structural heart disease, other)

    Agreement (Yes/No) of the user with the ECG-AI algorithm's interpretation. Agreement is defined as the user clicking on "thumbs up" on the platform.

    Time frame: 18 months

  8. Describe the agreement of the user with the ECG-AI algorithm's interpretation in the two subgroups.

    Agreement (Yes/No) of the user with the ECG-AI algorithm's interpretation Agreement is defined as the user clicking on "thumbs up" on the platform.

    Time frame: 18 months

  9. Evaluate the effect of displaying the ECHONeXT interpretation on the delay between the ECG and the TTE evaluation, by subgroups defined by the risk level of SHD (low/ intermediate/ high)

    Delay between the time of the first ECG opened in the platform and the TTE calculated as: Date of TTE evaluation - Date of access of the first ECG where an ECHONeXT interpretation was available, and a user consulted the ECG

    Time frame: 18 months

  10. Evaluate the model performance after applying continual learning

    We will re-train the DeepECG models using examples that were downvoted by users or that users " bookmarked " in addition to the previous ECGs that were used for training the model. Model performance will be compared using the DeLong test for the AUC and AUPRC before and after retraining the model. Users will not be exposed ot this new model.

    Time frame: 18 months

  11. Major adverse cardiovascular events

    Exploratory 12-month composite of all-cause death, myocardial infarction, stroke and any hospitalization. Obtain aggregated event counts by randomized arm and jurisdiction from ICES, RAMQ/MED-ÉCHO and German statutory health-insurance claims data, following linkage within each custodian's secure environment. No patient-level records are transferred to the study team. If a jurisdiction does not release counts, report available jurisdictions.

    Time frame: 12 months from the index ECG

  12. Resource utilization and cost-effectiveness

    Exploratory assessment of TTE prescriptions, completed volumes, priority mix and completion within 30 days. Economic evaluation uses a Canadian payer perspective over 12 months and reports cost per day earlier SHD diagnosis, incremental cost per additional 30-day SHD diagnosis, and 12-month budget impact. Costs include AI licensing and compute, coordinator time, TTE capacity and MACE costs; development costs are excluded from the primary ICER.

    Time frame: 12 months from the index ECG

  13. Patient experience with TTE referral and AI-supported care

    Exploratory satisfaction survey in 200 referred patients (100 per arm), selected through the platform and consented before survey administration. Assess wait times, communication clarity, AI comprehension and perceived care quality using a questionnaire adapted from the Patient Satisfaction Questionnaire. Report overall and by biological sex.

    Time frame: Through 12 months from the index ECG

07

Study locations

1 site
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jan 2026 → Dec 2027 and completion Jan 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Jun 17, 2024
StartActual
Apr 16, 2025
Primary completionEst.
Dec 2027was Jan 2026
CompletionEst.
Dec 2027was Jan 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 31, 2026→Dec 2027
Oct 13, 2026
Study completion
Jan 31, 2027→Dec 2027
Oct 13, 2026
Enrollment
16160→5700
Oct 13, 2026
Eligibility
Criteria largely rewritten (37 changes)
What changed in the criteria
Inclusion criteria
  • RemovedUsers
  • RemovedUsers who are providing clinical care and who read ECGs as part of their practice.
  • RemovedUsers who have provided informed consent to participate in the study.
  • RemovedUsers who have completed the required training on the use of the DeepECG platform.
  • RemovedECG
  • Removed12-lead ECGs recorded during the study period at the Montreal Heart Institute.
  • RemovedECGs of adequate technical quality for interpretation, as determined by the recording software and visual inspection.
  • AddedProviders:
  • Added- Licensed healthcare professionals (physicians, nurse practitioners, physician assistants, and residents) who interpret ECGs in ambulatory cardiology clinics or emergency departments and have authority to order TTEs.
  • Removed1. Patients aged 18 years or older
  • RemovedAdditional Inclusion criteria for the randomization part of the study
  • RemovedOutpatients or patients who presented at the ambulatory emergency department. The location will be determined according to the ECG where it was recorded which is entered by the ECG technician. These locations will be included for the eligibility of the randomization:
  • Removedlocations_to_keep = ['21_URGENCE AMBULATOIRE', '1_CARDIOLOGIE GENERALE', "17_CLINIQUE D'ARYTHMIE"]
  • RemovedNew patients without a prior formal evaluation by a cardiologist or internal medicine specialist for suspected or provisionally identified cardiac conditions, including:
  • RemovedArrhythmia
  • RemovedHeart Failure
  • RemovedCoronary Artery Disease
  • RemovedValvular Heart Disease
  • RemovedCardiomyopathy
  • RemovedOther cardiac conditions
  • RemovedPatients with previous TTE or MRI:
  • RemovedHave no documented history of any cardiac condition
  • RemovedNo transthoracic echocardiogram or MRI in the last 24 months (from any center)
  • AddedAdults aged 18 years or older presenting to outpatient cardiology clinics or ambulatory emergency departments with unknown structural heart disease (SHD) status.
  • AddedEither new patients with no prior cardiac diagnosis and no prior TTE on record, or surveillance patients whose most recent TTE was normal (no SHD) and performed at least 24 months ago.
  • AddedECGs:
  • Added- Standard 12-lead ECGs in XML format recorded after study initiation and successfully transmitted to DeepECG.ai.
Exclusion criteria
  • RemovedUsers
  • Removed1. Users who are unable to commit to the duration of the study (approximately 1 month minimum) or adhere to the study protocol.
  • RemovedAdditional Exclusion criteria for the randomization part of the study ECG
  • Removed1. ECG with too many artefacts or without any QRS visible as interpretated by the MUSE GE algorithm.
  • AddedProviders:
  • Added- None.
  • AddedPatients:
  • Added- Inpatient or hospitalized patients at the time of ECG. Patients randomized in the ambulatory emergency department who are subsequently hospitalized remain eligible.
  • AddedECGs:
  • Added- Failed automated quality checks, including poor technical quality or indiscernible QRS waveforms.
Oct 13, 2026
Interventions
Arms added: EchoNext AI-ECG risk score plus standard care·Standard care without displayed EchoNext guidance; arms removed: ECHONEXT interpretation·No ECHONEXT interpretation
Oct 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Assess the effect of displaying the ECHONeXT interpretation on the time to diagnosis of Structural Heart Disease (SHD)Now Proportion of randomized patients with TTE-documented structural heart disease within 30 daysTime frame: 18 months → 30 days from the index ECG
Oct 13, 2026
Secondary outcomes
23 added, 7 removed, 1 more
What changed in the outcomes
  • AddedProportion of randomized patients with TTE-documented structural heart disease within 12 monthsTime frame: 12 months from the index ECG
  • AddedTime from index ECG to clinical TTETime frame: 12 months from the index ECG
  • AddedIntended TTE priority at the index ECGTime frame: At baseline
  • AddedProvider concordance with EchoNext TTE recommendationsTime frame: At baseline
  • AddedTime from index ECG to SHD diagnosisTime frame: 12 months from the index ECG
  • AddedDiagnostic yield of clinical TTETime frame: 30 days from the index ECG
  • AddedNet clinical TTE volume per 100 randomized patientsTime frame: 30 days from the index ECG
  • AddedDocumented management change after SHD diagnosisTime frame: 12 months from the index ECG
  • AddedSHD diagnosis in low-risk patients by randomized armTime frame: 30 days from the index ECG
  • AddedEchoNext diagnostic performance and algorithmic fairnessTime frame: 30 days from the index ECG
  • AddedPre-display TTE intent versus final referral decisionTime frame: At baseline
  • AddedReduced left ventricular ejection fraction diagnosed on clinical TTETime frame: 30 days from the index ECG
  • AddedReduced right ventricular systolic function diagnosed on clinical TTETime frame: 30 days from the index ECG
  • AddedPulmonary hypertension diagnosed on clinical TTETime frame: 30 days from the index ECG
  • AddedValvular heart disease diagnosed on clinical TTETime frame: 30 days from the index ECG
  • AddedLeft ventricular hypertrophy diagnosed on clinical TTETime frame: 30 days from the index ECG
  • AddedPericardial effusion diagnosed on clinical TTETime frame: 30 days from the index ECG
  • RemovedAssess the effect of displaying the ECHONeXT interpretation on the rate of SHD diagnosis on TTETime frame: 18 months
  • RemovedEvaluate the effect of displaying the ECHONeXT interpretation on the delay between the ECG and the TTE evaluation for patients at high or intermediate risk of SHDTime frame: 18 months
  • RemovedAssess the agreement of the users with the ECG-AI algorithm's interpretationsTime frame: 18 months
  • RemovedDetermine the acceptability and usability of the DeepECG platform in clinical practice based on the end-of-study surveyTime frame: 18 months
  • RemovedDetermine the primary endpoint stratified according to the presence of a previous TTE > 24 months or no previous TTE (brand new patients)Time frame: 18 months
  • Addedother outcomeIntended TTE priority by ambulatory care settingTime frame: At baseline
  • Addedother outcomeProvider experience with EchoNext and DeepECGTime frame: At the end of the 27-month randomized main trial phase
  • Addedother outcome30-day SHD diagnosis by prior TTE status and biological sexTime frame: 30 days from the index ECG
  • Addedother outcomeMajor adverse cardiovascular eventsTime frame: 12 months from the index ECG
  • Addedother outcomeResource utilization and cost-effectivenessTime frame: 12 months from the index ECG
  • Addedother outcomePatient experience with TTE referral and AI-supported careTime frame: Through 12 months from the index ECG
  • Removedother outcomeCompare the TTE priority classification assigned by the user between the intervention and the control groupTime frame: 18 months
  • Removedother outcomeCompare the TTE priority classification assigned by the user between the intervention and the control group stratified by location (emergency vs outpatientTime frame: 18 months
  • …and 1 more, on the record history on ClinicalTrials.gov ↗
Oct 13, 2026
Title
Harnessing ECG Artificial Intelligence for Rapid Treatment and Accurate Identification of Structural Heart DiseaseInterpretation
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Jan 31, 2026→Dec 2027
    Study completion Jan 31, 2027→Dec 2027
    Enrollment 16160→5700
    Eligibility Criteria largely rewritten (37 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedUsers
    • RemovedUsers who are providing clinical care and who read ECGs as part of their practice.
    • RemovedUsers who have provided informed consent to participate in the study.
    • RemovedUsers who have completed the required training on the use of the DeepECG platform.
    • RemovedECG
    • Removed12-lead ECGs recorded during the study period at the Montreal Heart Institute.
    • RemovedECGs of adequate technical quality for interpretation, as determined by the recording software and visual inspection.
    • AddedProviders:
    • Added- Licensed healthcare professionals (physicians, nurse practitioners, physician assistants, and residents) who interpret ECGs in ambulatory cardiology clinics or emergency departments and have authority to order TTEs.
    • Removed1. Patients aged 18 years or older
    • RemovedAdditional Inclusion criteria for the randomization part of the study
    • RemovedOutpatients or patients who presented at the ambulatory emergency department. The location will be determined according to the ECG where it was recorded which is entered by the ECG technician. These locations will be included for the eligibility of the randomization:
    • Removedlocations_to_keep = ['21_URGENCE AMBULATOIRE', '1_CARDIOLOGIE GENERALE', "17_CLINIQUE D'ARYTHMIE"]
    • RemovedNew patients without a prior formal evaluation by a cardiologist or internal medicine specialist for suspected or provisionally identified cardiac conditions, including:
    • RemovedArrhythmia
    • RemovedHeart Failure
    • RemovedCoronary Artery Disease
    • RemovedValvular Heart Disease
    • RemovedCardiomyopathy
    • RemovedOther cardiac conditions
    • RemovedPatients with previous TTE or MRI:
    • RemovedHave no documented history of any cardiac condition
    • RemovedNo transthoracic echocardiogram or MRI in the last 24 months (from any center)
    • AddedAdults aged 18 years or older presenting to outpatient cardiology clinics or ambulatory emergency departments with unknown structural heart disease (SHD) status.
    • AddedEither new patients with no prior cardiac diagnosis and no prior TTE on record, or surveillance patients whose most recent TTE was normal (no SHD) and performed at least 24 months ago.
    • AddedECGs:
    • Added- Standard 12-lead ECGs in XML format recorded after study initiation and successfully transmitted to DeepECG.ai.
    Exclusion criteria
    • RemovedUsers
    • Removed1. Users who are unable to commit to the duration of the study (approximately 1 month minimum) or adhere to the study protocol.
    • RemovedAdditional Exclusion criteria for the randomization part of the study ECG
    • Removed1. ECG with too many artefacts or without any QRS visible as interpretated by the MUSE GE algorithm.
    • AddedProviders:
    • Added- None.
    • AddedPatients:
    • Added- Inpatient or hospitalized patients at the time of ECG. Patients randomized in the ambulatory emergency department who are subsequently hospitalized remain eligible.
    • AddedECGs:
    • Added- Failed automated quality checks, including poor technical quality or indiscernible QRS waveforms.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Assess the effect of displaying the ECHONeXT interpretation on the time to diagnosis of Structural Heart Disease (SHD)Now Proportion of randomized patients with TTE-documented structural heart disease within 30 daysTime frame: 18 months → 30 days from the index ECG
    Secondary outcomes 23 added, 7 removed, 1 more
    What changed in the outcomes
    • AddedProportion of randomized patients with TTE-documented structural heart disease within 12 monthsTime frame: 12 months from the index ECG
    • AddedTime from index ECG to clinical TTETime frame: 12 months from the index ECG
    • AddedIntended TTE priority at the index ECGTime frame: At baseline
    • AddedProvider concordance with EchoNext TTE recommendationsTime frame: At baseline
    • AddedTime from index ECG to SHD diagnosisTime frame: 12 months from the index ECG
    • AddedDiagnostic yield of clinical TTETime frame: 30 days from the index ECG
    • AddedNet clinical TTE volume per 100 randomized patientsTime frame: 30 days from the index ECG
    • AddedDocumented management change after SHD diagnosisTime frame: 12 months from the index ECG
    • AddedSHD diagnosis in low-risk patients by randomized armTime frame: 30 days from the index ECG
    • AddedEchoNext diagnostic performance and algorithmic fairnessTime frame: 30 days from the index ECG
    • AddedPre-display TTE intent versus final referral decisionTime frame: At baseline
    • AddedReduced left ventricular ejection fraction diagnosed on clinical TTETime frame: 30 days from the index ECG
    • AddedReduced right ventricular systolic function diagnosed on clinical TTETime frame: 30 days from the index ECG
    • AddedPulmonary hypertension diagnosed on clinical TTETime frame: 30 days from the index ECG
    • AddedValvular heart disease diagnosed on clinical TTETime frame: 30 days from the index ECG
    • AddedLeft ventricular hypertrophy diagnosed on clinical TTETime frame: 30 days from the index ECG
    • AddedPericardial effusion diagnosed on clinical TTETime frame: 30 days from the index ECG
    • RemovedAssess the effect of displaying the ECHONeXT interpretation on the rate of SHD diagnosis on TTETime frame: 18 months
    • RemovedEvaluate the effect of displaying the ECHONeXT interpretation on the delay between the ECG and the TTE evaluation for patients at high or intermediate risk of SHDTime frame: 18 months
    • RemovedAssess the agreement of the users with the ECG-AI algorithm's interpretationsTime frame: 18 months
    • RemovedDetermine the acceptability and usability of the DeepECG platform in clinical practice based on the end-of-study surveyTime frame: 18 months
    • RemovedDetermine the primary endpoint stratified according to the presence of a previous TTE > 24 months or no previous TTE (brand new patients)Time frame: 18 months
    • Addedother outcomeIntended TTE priority by ambulatory care settingTime frame: At baseline
    • Addedother outcomeProvider experience with EchoNext and DeepECGTime frame: At the end of the 27-month randomized main trial phase
    • Addedother outcome30-day SHD diagnosis by prior TTE status and biological sexTime frame: 30 days from the index ECG
    • Addedother outcomeMajor adverse cardiovascular eventsTime frame: 12 months from the index ECG
    • Addedother outcomeResource utilization and cost-effectivenessTime frame: 12 months from the index ECG
    • Addedother outcomePatient experience with TTE referral and AI-supported careTime frame: Through 12 months from the index ECG
    • Removedother outcomeCompare the TTE priority classification assigned by the user between the intervention and the control groupTime frame: 18 months
    • Removedother outcomeCompare the TTE priority classification assigned by the user between the intervention and the control group stratified by location (emergency vs outpatientTime frame: 18 months
    • …and 1 more, on the record history on ClinicalTrials.gov ↗
    Interventions Arms added: EchoNext AI-ECG risk score plus standard care·Standard care without displayed EchoNext guidance; arms removed: ECHONEXT interpretation·No ECHONEXT interpretation
    Title Harnessing ECG Artificial Intelligence for Rapid Treatment and Accurate Identification of Structural Heart DiseaseInterpretation
    + 3 other changes: verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06462989
Responsible party
Robert Avram (Interventional Cardiologist, Montreal Heart Institute) — Principal investigator
First posted
Jun 17, 2024
Start date
Apr 16, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion